Comparison of the immunogenicity of mRNA-encoded and protein HIV-1 Env–ferritin nanoparticle designs
Journal of Virology · 17.09.2024 · 98 (9)
DOI: 10.1128/jvi.00137-24 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of Virology, erschienen am 17.09.2024. Verfasst von Zekun Mu und 28 weiteren Autor:innen. Beteiligte Einrichtung: Department of Integrative Immunobiology, Duke University School of Medicine, Durham, North Carolina, USA. Hauptthemen laut MEDLINE: Nanoparticles, HIV-1, Ferritins. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NIH HHS, HHS | NIH | National Institute of Allergy and Infectious Diseases.
Abstract (Originalsprache)
Nucleoside-modified mRNA technology has revolutionized vaccine development with the success of mRNA COVID-19 vaccines. We used modified mRNA technology for the design of envelopes (Env) to induce HIV-1 broadly neutralizing antibodies (bnAbs). However, unlike SARS-CoV-2 neutralizing antibodies that are readily made, HIV-1 bnAb induction is disfavored by the immune system because of the rarity of bnAb B cell precursors and the cross-reactivity of bnAbs targeting certain Env epitopes with host molecules, thus requiring optimized immunogen design. The use of protein nanoparticles (NPs) has been reported to enhance B cell germinal center responses to HIV-1 Env. Here, we report our experience with the expression of Env–ferritin NPs compared with membrane-bound Env gp160 when encoded by modified mRNA. We found that well-folded Env–ferritin NPs were a minority of the protein expressed by an mRNA design and were immunogenic at 20 µg but minimally immunogenic in mice at 1 µg dose in vivo and were not expressed well in draining lymph nodes (LNs) following intramuscular immunization. In contrast, mRNA encoding gp160 was more immunogenic than mRNA encoding Env–NP at 1 µg dose and was expressed well in draining LN following intramuscular immunization. Thus, analysis of mRNA expression in vitro and immunogenicity at low doses in vivo are critical for the evaluation of mRNA designs for optimal immunogenicity of HIV-1 immunogens. IMPORTANCE An effective HIV-1 vaccine that induces protective antibody responses remains elusive. We have used mRNA technology for designs of HIV-1 immunogens in the forms of membrane-bound full-length envelope gp160 and envelope ferritin nanoparticle. Here, we demonstrated in a mouse model that the membrane-bound form induced a better response than envelope ferritin nanoparticle because of higher in vivo protein expression. The significance of our research is in highlighting the importance of analysis of mRNA design expression and low-dose immunogenicity studies for HIV-1 immunogens before moving to vaccine clinical trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Integrative Immunobiology, Duke University School of Medicine, Durham, North Carolina, USA.
- Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, USA.
- Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- Department of Pathology and Laboratory Medicine, Children Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
- Penn Institute for RNA Innovation, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- Acuitas Therapeutics, Vancouver, British Columbia, Canada.
ORCID-Profile: Zekun Mu, Drew Weissman, Kevin O Saunders, Barton F Haynes
Förderung
- NIAID NIH HHS
- NIH HHS
- HHS | NIH | National Institute of Allergy and Infectious Diseases
Zitieren
APA
Mu, Z., Whitley, J., Martik, D., Sutherland, L., Newman, A., Barr, M., Parks, R., Wiehe, K., Cain, D. W., Hodges, K. Z., Venkatayogi, S., Lee, E. M., Smith, L., Mansouri, K., Edwards, R. J., Wang, Y., Rountree, W., Alameh, M. G., Tam, Y., …, & Haynes, B. F. (2024). Comparison of the immunogenicity of mRNA-encoded and protein HIV-1 Env–ferritin nanoparticle designs. Journal of Virology, 98(9). https://doi.org/10.1128/jvi.00137-24
Vancouver
Mu Z, Whitley J, Martik D, Sutherland L, Newman A, Barr M, et al. Comparison of the immunogenicity of mRNA-encoded and protein HIV-1 Env–ferritin nanoparticle designs. Journal of Virology. 2024;98(9). doi:10.1128/jvi.00137-24
BibTeX
@article{Mu2024,
author = {Mu, Zekun and Whitley, Jill and Martik, Diana and Sutherland, Laura and Newman, Amanda and Barr, Maggie and Parks, Robert and Wiehe, Kevin and Cain, Derek W and Hodges, Katrina Z and Venkatayogi, Sravani and Lee, Esther M and Smith, Lena and Mansouri, Katayoun and Edwards, Robert J and Wang, Yunfei and Rountree, Wes and Alameh, Mohamad-Gabriel and Tam, Ying and Barbosa, Christopher and Tomai, Mark and Lewis, Mark G and Santrai, Sampa and Maughan, Maureen and Tian, Ming and Alt, Frederick W and Weissman, Drew and Saunders, Kevin O and Haynes, Barton F},
title = {Comparison of the immunogenicity of mRNA-encoded and protein HIV-1 Env–ferritin nanoparticle designs},
journal = {Journal of Virology},
year = {2024},
volume = {98},
number = {9},
doi = {10.1128/jvi.00137-24}
}
EUVIMED